

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/679,279	ATTY. DOCKET NO.: C1039.70077US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
		APPLICANT: Arthur M. Krieg, et al.	
		GROUP ART UNIT: 1632	EXAMINER: Not yet assigned
Sheet	1	of	4

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JE	*	5,417,972		Bhat et al.	05/23/1995
	*	5,445,938		Hanai et al.	08/29/1995
	*	5,491,088		Hellstrom et al.	02/13/1996
	*	5,679,647	B1	Carson et al.	10/21/1997
	*	5,756,097		Landucci et al.	05/26/1998
	*	5,780,448	B1	Davis	07/14/1998
	*	5,837,243		Deo et al.	11/17/1998
	**	6,225,292	B1	Raz , et al.	05/01/2001
	*	6,426,334	B1	Agrawal et al.	07/30/2002
	**	6,514,948	B1	Raz, et al.	02/04/2003
	**	6,534,062	B2	Krieg, et al.	03/18/2003
	**	6,552,006	B2	Raz et al.	04/22/2003
	**	6,562,798	B1	Schwartz	05/13/2003
	**	6,589,940	B1	Raz et al.	07/08/2003
	**	6,610,661	B1	Carson et al.	08/26/2003
	**	6,653,292	B1	Krieg et al.	11/25/2003
	**	US 2001/0046967	A1	Van Nest	11/29/2001
	**	US 2002/0028784	A1	Van Nest	03/07/2002
	**	US 2002/0055477	A1	Nest	05/09/2002
	**	US 2002/0098199	A1	Nest et al.	07/25/2002
	**	US 2002/0107212	A1	Van Nest et al.	08/08/2002
	**	US 2002/0142978	A1	Van Nest et al.	10/03/2002
	**	US 2002/0156033	A1	Raz et al.	10/24/2002
	**	US 2003/0049266	A1	Bratzler et al.	03/13/2003
	**	US 2003/0050263	A1	Fearon et al.	03/13/2003
	**	US 2003/0078223	A1	Krieg et al.	04/24/2003
	**	US 2003/0092663	A1	Raz et al.	05/15/2003
	**	US 2003/0109469	A1	Raz	06/12/2003
	**	US 2003/0119773	A1	Carson et al.	06/26/2003
	**	US 2003/0129251	A1	Raz et al.	07/10/2003
	**	US 2003/0133988	A1	Van Nest et al.	07/17/2003
	**	US 2003/0143213	A1	Fearon et al.	07/31/2003
	**	US 2003/0147870	A1	Raz et al.	08/07/2003
	**	US 2003/0175731	A1	Raz et al.	09/18/2003
	**	US 2003/0186921	A1	Rearon et al	10/02/2003
JE	**	US 2003/0199466	A1	Fearon et al.	10-23-2003

CANCELED

JAN 09 2004

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279		ATTY. DOCKET NO.: C1039.70077US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 8248	
				APPLICANT: Arthur M. Krieg, et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not yet assigned	
Sheet	2	of	4				

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JE	**	US 2003/0212028	A1	Raz et al.	11-13-2003
JE	**	US 2003/0216340	A1	Van Nest et al.	11-20-2003



**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
JE	*	WO	96/02560	A1	University of NC at Chapel Hill	02/01/1996	
JE	B1	WO	99/62923	A2	Dynavax Tech. Corp.	12/09/1999	
JE	B2	WO	00/20039	A1	Regents of the University of CA	04/13/2000	
JE	B3	WO	00/62787	A1	Regents of the University of CA	10/26/2000	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
JE	*	AGGARWAL, S.K. et al., "Cell-Surface-Associated Nucleic Acid in Tumorigenic Cells Made Visible with Platinum-Complexes by Electron Microscopy", <i>Proc. Nat. Acad. Sci. USA</i> , March 1975, Pages 928-932, Vol. 72, No. 3		
JE	*	BERNHARD, M., et al., "Monocyte Macrophage Mediated Antibody Dependent and Independent Cell Mediated Cytotoxicity in Normals and Cancer Patients, ABSTRACT, Proceedings of AACR and ASCO, 22:372, c-159		
JE	*	COHEN, J., et al., "IL-12 Deaths: Explanation and a Puzzle", <i>Science</i> , 10:270:5238:908		
JE	*	COSSUM, P., et al., "Pharmacokinetics of a <sup>14</sup> C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 269:1:89-94, (1993)		
JE	*	DOE, B., et al., "Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells", <i>Proc. Natl. Acad. Sci.</i> , 93:8578-8583, (1996)		
JE	*	GATELY, M., et al., "Interleukin-12: A Recently Discovered Cytokine with potential for Enhancing Cell-Mediated Immune Responses to Tumors", <i>Cancer Investigation</i> , 11:4:500-506, (1993)		
JE	*	HAMBLIN, T., et al., "Ex Vivo Activation and Retransfusion of White Blood Cells", <i>Curr Stud Hematol Blood Transf.</i> , 57:249-266, (1990)		
JE	*	HARTMANN, G., et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells", <i>Proc. Natl. Acad. Sci.</i> , 96:9305-9310, (1999)		
JE	*	KATAOKA, T., et al. "Immunotherapeutid potential in Guinea-Pig Tumor Model of Deoxyribonucleic Acid From Mycobacterium Bovix BCG Complexed with Poly-L-Lysine and Carboxy-Methylcellulose", <i>Jpn J. Med. Sci. Biol.</i> 43:171-182, (1990)		
JE	*	KLINMAN, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines", <i>J. of Immunol.</i> , 1997, Pages 3635-3639, Vol. 158, No. 8, The American Association of Immunologists		
JE	*	KOLITZ, J., et al., "The Immunotherapy of Human Cancer with Interleukin 2: Present Status and Future Directions", <i>Cancer Investigation</i> , 9:5:529-542, (1991)		



CANCO



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: May 14, 2003	CONFIRMATION NO.: 8248
		APPLICANT: Arthur M. Krieg, et al.	
		GROUP ART UNIT: 1632	EXAMINER: Not yet assigned
Sheet	3	of	4

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
JE	*	KURAMOTO, et al., "In Situ Infiltration of Natural Killer-Like Cell Induced by Intradermal Injection of the Nucleic Acid Fraction from BCG", <i>Microbiol. Immunol.</i> , 33:11:929-940, (1989)	
	*	KURAMOTO, E., et al., "Changes of host cell infiltration into meth a fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>Int. J. Immunopharmacol.</i> 14:5:773-782, (1992)	
	*	Lacour, J., et al., "Clinical Trials Using Polyadenylic-Polyuridylic Acid as an Adjuvant to Surgery in Treating Different Human Tumors, <i>J of Biological Response Modifiers</i> , 4:538-543, (1985)	
	*	LIPFORD, G.B. et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>Eur. J. Immunol.</i> , 1997, Pages 2340-2344, Vol. 27	
	*	LIPFORD, G.B. et al, "Bacterial DNA as immune cell activator", <i>Inst. of Med. Microb., Immunol. and Hygiene</i> , 1998, Pages 496-500, Elsevier Science	
	*	MASHIBA, H., et al., "In Vitro Augmentation of Natural Killer Activity of Peripheral Blood Cells From Cancer Patients by a DNA-Fraction From Mycobacterium Bovis BCG", <i>Jpn J. Med. Sci. Biol.</i> , 41:197-202, (1988)	
	*	MORAHAN, P., et al., "Comparative Analysis of Modulators of Nonspecific Resistance Against Microbial Infections", <i>Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance</i> , 313-324, (1987)	
	*	REISFELD, R., et al., "Monoclonal Antibodies in Cancer Therapy", <i>Clinics in-Laboratory Medicine</i> , 12:2:201-216, (1992)	
	*	ROSENBERG, S., et al., "Immunotherapy of Cancer by Systemic Administration of Lymphoid Cells Plus Interleukin-2", <i>Journal of Biological Response Modifiers</i> , 3:501-511, (1984)-	
	*	ROSENBERG, S., et al., "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukins-2 to patients with metastatic cancer", <i>The New England Journal of Medicine</i> , 113:23:1485-1492, (1985)	
	*	SHIMADA, S., et al., "In Vivo Augmentatio of Natural Killer Cell Activity With A Deoxyribonucleic Acid Fraction of BCG", <i>Jpn J. Cancer Res.</i> , 77:808-816, (1986)	
	*	SHIMADA, S., et al., "Antitumor Acitivity of the DNA Fraction from Mycobacterium bovis BCG. II> Effects on Various Syngeneic Mouse Tumors", <i>JNCI</i> , 74:3:681-688, (1985)	
	*	STEVENSON, H., et al., "The Treatment of Cancer with Activated Cytotoxic Leukocyte Subsets", <i>Artif Organs</i> , 12:2:128136, 1988	
	*	STULL, R.A. et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Research</i> , 1995, Pages 465-483, Vol. 12, No. 4, Plenum Publishing Corp.	
	*	SUN, S. et al., "Mitogenicity of DNA from Different Organisms for Murine B Cells", <i>The Journal of Immunology</i> , 1997, Pages 3119-3125, The American Association of Immunologists	
	*	THREADGILL, D.S. et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> , 1998, Pages 76-82, Vol. 16, No. 1, Elsevier Science Ltd.	
	*	TOPALIAN, S., et al., "Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials", <i>J of Immunological Methods</i> , 102:127-141, (1987)	
	*	TORPEY III, D., et al., "Effects of Adoptive Immunotherapy with Autologous CD8+ t Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity, <i>Clinical Immunology and Immunopathology</i> , 68:3:263-272, (1993)	
JE	*	VOGELS, M., et al., "Use of Immune Modulators in nonspecific Therapy of Bacterial Infections", <i>Antimicrobial Agents and Chemotherapy</i> , 36:1:1-5, (1992)	



<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
		FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
		APPLICANT: Arthur M. Krieg, et al.	
		GROUP ART UNIT: 1632	EXAMINER: Not yet assigned
Sheet	4	of	4

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
JE	*	WILTROUT, R.H., et al., "Immunomodulation of Natural Killer Activity by Polyribonucleotides", <i>Journal of Biological Response Modifiers</i> , 1985, Pages 512-517, Vol. 4, No. 5, New Raven Press, NY	
JE	*	WOOLDRIDGE, J., et al., "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma", <i>Blood</i> , 89:8:2994-2998, (1997)	
JE	*	WOOLDRIDGE, J.E. et al., "Select Unmethylated CpG Oligodeoxynucleotides Improve Antibody Dependent Cellular Cytotoxicity <i>in Vitro</i> of Both Murine and Human B Cell Lymphomas", <i>Blood</i> , December 1995, Page 2877, Abstract, Vol. 86	
JE	*	WOOLDRIDGE, J.E. et al., "Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity <i>in vitro</i> and <i>in vivo</i> ", Proceedings of the American Association for Cancer Research #3253, March 1996, Page 477, Abstract, Vol. 37	

EXAMINER /Janet Epps Ford/	DATE CONSIDERED 09/18/2006
----------------------------	----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in one of the prior applications, Serial No. 08/386,063, filed February 7, 1995, Serial No. 08/738,652, filed October 30, 1996, Serial No. 09/337,619, filed June 21, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

\*\* copies of these patents and patent applications are not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



<b>FORM PTO-1449 (Modified)</b>	<b>ATTY. DOCKET NO.</b>	<b>SERIAL NO</b>
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>	C01039.70077.US	Not Yet Assigned
<b>APPLICANT</b> Krieg		
<b>FILING DATE</b> July14, 2003		<b>GROUP</b> Not Yet Assigned

### U.S. PATENT DOCUMENTS




Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
*		3,906,092	09/16/75	Hilleman et al.			
*		5,248,670	09/28/93	Draper et al.	514	44	
*		5,585,479	12/17/96	Hoke et al.	536	24.5	
*		5,663,153	09/02/97	Hutcherson et al.	514	44	
*		5,723,335	03/03/98	Hutcherson et al.	435	375	
*		5,786,189	07/28/98	Locht et al.	435	172.3	
*		5,849,719	12/15/98	Carson et al.	514	44	
*		6,498,148	12/24/02	Raz			

### FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	No
*	WO 91/12811	09/05/91	PCT	A61K	31/70		
*	0468520 A3	01/29/92	EPO	A61K	31/70		
*	WO 92/03456	03/05/92	PCT	C07H	15/12		
*	WO 92/18522	10/29/92	PCT	C07H	21/00		
*	WO 92/21353	12/10/92	PCT	A61K	31/70		
*	0302758 81	03/16/94	EPO	C12N	15/37		
*	WO 94/19945	09/15/94	PCT	A01N	43/04		
*	WO 95/05853	03/02/95	Regents of the University of CA				
*	WO 95/26204	10/95	PCT	A61K	48/00		
*	WO 96/02555	02/01/96	PCT				
*	WO 96/35782	11/14/96	Applied Research Systems				
*	WO 97/28259	08/07/97	PCT	C12N	15/00		
*	WO 98/18810	05/07/98	PCT	C07H	21/00		
*	WO 98/37919	09/03/98	PCT	A61K	49/00		
*	WO 98/40100	09/17/98	PCT	A61K	39/39		
*	WO 98/52581	11/26/98	PCT	A61K	35/00		
*	WO 98/14210	04/09/98	PCT	A61K	39/35		

<b>FORM PTO-1449 (Modified)</b>				<b>ATTY. DOCKET NO.</b>		<b>SERIAL NO</b>			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				C01039.70077.US		Not Yet Assigned			
				APPLICANT Krieg					
				FILING DATE July 14, 2003		GROUP Not Yet Assigned			
*		WO 98/16247	04/23/98	Regents of the University of CA					
*		WO 98/32462	07/30/98	Wagner et al.					
*		WO 98/49288	11/05/98	Hybridon, Inc.					
*		WO 98/55495	12/10/98	Dynavax Technologies Corp.					
*		WO 99/11275	03/11/99	Regents of the University of CA					
<b>OTHER ART</b>									
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)									
*		Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, 7 Jun 1994.							
*		Angier, N., Microbe DNA Seen as Alien By Immune System, <i>New York Times</i> , 4/11/95							
*		Azad RF et al., Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region. <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, September, 1993.							
*		Azuma, Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli, <i>Kekkaku</i> , Vol. 69, 9:45-55, 1992.							
*		Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> 157(5):1840-5, 1996.							
*		Bayever, E., Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial, <i>Antisense Res. &amp; Dev.</i> (1993), 3:383-390.							
*		Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest</i> 76(6):2182-90, 1985.							
*		Berg DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. <i>J Clin Invest</i> 96(5):2339-47, 1995.							
*		Blanchard DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. <i>J Immunol</i> 136(3):963-70, 1986.							
*		Blaxter et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Molecular and Biochemical Parasitology</i> , 77:77-93.							
*		Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> 7(5):461-71, Oct 1997.							
*		Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J. Lab Clin Med</i> 128(3):329-38, Sep 1996.							
*		Branda et al., Immune Stimulation by an Antisense Oligomer Complementary to the rev gene of HIV-1. <i>Biochemical Pharmacology</i> , Vol. 45, 10:2037-2043, 1993.							
*		Briskin M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation. <i>Mol Cell Biol</i> 10(1):422-5, Jan 1990.							
*		Chace, J. et al., Regulation of Differentiation in CD5+ and Conventional B Cells, <i>Clinical Immunology and Immunopathology</i> , (1993), 68:3:327-332.							

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C01039.70077.US	Not Yet Assigned
		APPLICANT Krieg	
		FILING DATE July 14, 2003	GROUP Not Yet Assigned
*	Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol</i> 64(1):264-77, Jan 1990.		
*	Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity... <i>Exp Med</i> 186(10):1623-31, 17 Nov 1997.		
*	Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol</i> 156(12):4570-5, 15 Jun 1996.		
*	Crosby et al., The Early Responses Gene FGFI-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family. <i>Mol. Cell. Biol.</i> , 2:3835-3841, 1991.		
*	Crystal, Transfer of Genes to Humans: Early Lessons and Obstacles to Success. <i>Science</i> , Vol. 270, pp. 404-410, 1995.		
*	D'Andrea A et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell-stimulatory factor/IL-12 synthesis in accessory cells. <i>J Exp Med</i> 178(3):1041-8, 1993.		
*	Englisch et al., Chemically Modified Oligonucleotides as Probes and Inhibitors, <i>Angew. Chem. Int. Ed. Engl.</i> , 30:613-629, 1991.		
*	Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med</i> 187(4):561-9, 16 Feb 1998.		
*	Etlinjer, Carrier sequence selection - one key to successful vaccines, <i>Immunology Today</i> , Vol. 13, 2:52-55, 1992.		
*	Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. <i>Chemical Abstracts</i> , 120:15, Abstract No. 182630 (April 29, 1994).		
*	Froehler, B.C. et al., Synthesis of DNA via deoxynucleotide H-phosphonate intermediates, <i>Nucleic Acid Research</i> , 14(13):5399, 1986.		
*	Gura, T., Antisense Has Growing Pains. <i>Science</i> (1995), 270:575-576.		
*	Hadden J et al., Immunostimulants. <i>TIPS</i> , (1993), 141:169-174.		
*	Hadden J et al., Immunopharmacology, <i>JAMA</i> , (1992) 268:20:2964-2969.		
*	Halpern MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> 167(1):72-8, 1996.		
*	Hatzfeld J., Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor $\beta$ 1 or Rb Oligonucleotides, <i>J. Exp. Med.</i> , (1991) 174:925-929.		
*	Highfield PE, Sepsis: the More, the Murkier. <i>Biotechnology</i> , 12:828, August 12, 1994.		
*	Hoeffler JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> 5(2):256-66, Feb 1991.		
*	Iguchi-Arigo SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989.		
*	Iverson, P., et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against HIV from Human Immunodeficiency Virus Type 1 in the Adult male Rhesus Following Single Injections and Continuous Infusion", <i>Antisense Research and Development</i> , (1994), 4:43-52		
*	Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> 150(9):3713-27, 1 May 1993		

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C01039.70077.US	Not Yet Assigned
		APPLICANT: Krieg	
		FILING DATE July 14, 2003	GROUP Not Yet Assigned
*		Jakway JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. <i>J Immunol</i> 137(7):2225-31, 1 Oct 1986.	
*		Jaroszewski JW and Cohen JS, Cellular uptake of antisense oligonucleotides. <i>Adv Drug Delivery Rev</i> 6(3):235-50, 1991.	
*		Kataoka, T. et al., Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of Mycobacterium bovis BCG, <i>Jpn. J. Cancer Res.</i> , 83:244, 1992.	
*		Kimura Y et al., Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN, <i>J. Biochem.</i> , Vol. 116, 5:991-994, 1994.	
*		Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A, 1996.	
*		Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A, 1997.	
*		Kline JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A, 1997.	
*		Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83, 1996.	
*		Krajewski, W., et al., "A Monomeric Derivative of the Cellular Transcription Factor CREB Functions as a Constitutive Activator", <i>Molecular and Cellular Biology</i> , 14:11:7204-7210, (1994)	
*		Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med</i> 128(2):128-33, 1996.	
*		Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991.	
*		Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996.	
*		Krieg AM et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proc. Natl. Acad. Sci.</i> , (1993), 90:1048-1052	
*		Krieg AM et al., "CpG DNA: A Pathogenic Factor in Systemic Lupus Erythematosus?", <i>Journal of Clinical Immunology</i> , (1995) 15:6:284-292.	
*		Krieg AM et al., "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?", <i>Antisense Research and Development</i> , (1995), 5:241	
*		Krieg AM et al., "Leukocyte Stimulation by Oligodeoxynucleotides", <i>Applied Antisense Oligonucleotide Technology</i> , (1998), 431-448	
*		Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 1995.	
*		Krieg AM et al., "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> , Vol. 6, pp. 23-27, Jan 1998.	
*		Krieg AM et al., "A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, the <i>Journal of Immunology</i> , Vol. 143, 2448-2451,	
*		Kuramoto et al., Oligonucleotide Sequences Required for Natural Killer Cell Activation, <i>Jpn. J. Cancer Res.</i> , 83:1128-1131, November 1992.	
*		Kwok, R., et al., "Nuclear protein CBP is a coactivator for the transcription factor CREB", <i>Nature</i> , 370:223-226, (1994)	
*		Lacour, J., Clinical Trials Using Polyadenylic-Polyuridylic Acid as an Adjuvant to Surgery in Treating Different Human Tumors, <i>J. Biological Response Modifiers</i> , 4(5):538, 1985.	



<b>FORM PTO-1449 (Modified)</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>	<b>ATTY. DOCKET NO.</b>  C01039.70077.US	<b>SERIAL NO</b>  Not Yet Assigned
<b>APPLICANT</b> Krieg		
<b>FILING DATE</b> July 14, 2003		<b>GROUP</b> Not Yet Assigned
*	Lee, K., et al., "Transcriptional regulation by CREB and its relatives", <i>Biochemica et Biophysica Acta</i> , 1174:221-233, (1993)	
*	Leonard et al., Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG). <i>Biochemistry</i> , 31(36):8415-8420, 1992.	
*	Macfarlane DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> 160(3):1122-31, Feb 1 1998.	
*	Mastrangelo et al. <i>Seminars in Oncology</i> . Vol. 23, 1:4-21, 1996.	
*	Matson S and Krieg AM, Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992.	
*	McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> 3(4):309-22, Winter 1993.	
*	Messina et al., The Influence of DNA Structure on the <i>in vitro</i> Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens. <i>Cellular Immunology</i> , 147:148-157, 1993.	
*	Messina et al., Stimulation of <i>in vitro</i> Murine Lymphocyte Proliferation by Bacterial DNA. <i>J. Immunol.</i> , Vol. 147, 6:1759-1764, September 15, 1991.	
*	Mojcik, C., et al., "Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effect in vivo in a Sequence-Specific Manner", <i>Clinical Immunology and Immunopathology</i> , (1993), 67:2:130-136	
*	Mottram et al., A novel CDC2-related protein kinase from leishmania mexicana LmmCRK1 is post-translationally regulated during the life cycle. <i>J. Biol. Chem.</i> 268:28, 21044-21052 (October 1993).	
*	New England BIOLABS 1988-1989 Catalog	
*	Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. <i>Nature</i> 385:721-725, 20 Feb 1997.	
*	Paca-Uccaralertkun, S., et al., "In Vitro Selection of DNA Elements Highly Responsive to the Human T-Cell Lymphotropic Virus Type I Transcriptional Activator, Tax, <i>Molecular and Cellular Biology</i> , 14:1:456-462, (1994)	
*	Pisetsky, D., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Repairs</i> , (1993) 18:217-221	
*	Pisetsky et al., Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus. <i>Life Science</i> , Vol. 54, pp. 101-107 (1994).	
*	Pisetsky, The Immunological Properties of DNA, <i>The Journal of Immunology</i> , pp. 421-423 (1996).	
*	Pisetsky, Immunological Consequences of Nucleic Acid Therapy, <i>Antisense Research and Development</i> , 5:219-225 (1995).	
*	Raz E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, 14 May 1996.	
*	Roman M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med</i> 3(8):849-54, Aug 1997.	
*	Sarmiento, U., et al., "In Vivo Toxicological Effects of rel A Antisense Phosphorothioates in CD-1 Mice", <i>Antisense Research and Development</i> , 4:99-107, (1994)	
*	Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, <i>Science</i> , Vol. 273, pp. 352-354, 1996.	

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C01039.70077.US	Not Yet Assigned
		APPLICANT Krieg	
		FILING DATE July 14, 2003	GROUP Not Yet Assigned
*		Schnell et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators. <i>Eur. J. Biochem.</i> , 200:487-493.	
*		Schwartz DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. <i>Am J Physiol</i> 267(5 Pt 1):L609-17, 1994.	
*		Schwartz DA et al., The role of endotoxin in grain dust-induced lung disease. <i>Am J Respir Crit Care Med</i> 152(2):603-8, 1995.	
*		Schwartz DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> 100(1):68-73, 1 Jul 1997.	
*		Shirakawa T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> 275(5296):77-9, 3 Jan 1997.	
*		Sparwasser T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> 27(7):1671-9, Jul 1997.	
*		Stein CA et al., Oligonucleotides as inhibitors of gene expression: a review. <i>Cancer Research</i> , 48:2659-2668, 1988.	
*		Stull et al., Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects; <i>Pharmaceutical Res.</i> , Vol. 12, 4:465-483, 1995.	
*		Subramanian et al., Theoretical Considerations on the "Spine of Hydration" in the Minor Groove of d(CGCGAATTCGCG) d(GCGCTTAAGCGC): Monte Carlo Computer Simulation. <i>Proc. Nat'l. Acad. Sci. USA</i> , 85:1836-1840, 1988.	
*		Tanaka T et al., An antisense Oligonucleotide complementary to a sequence in IG2b increases G2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. <i>J. Exp. Med.</i> , 175:597-607, 1992.	
*		Thorne PS., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. <i>Am J Ind Med</i> 25(1):109-12, 1994.	
*		Tokunaga T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of <i>Mycobacterium bovis</i> BCG Induce Interferons and Activate Natural Killer Cells, <i>Microbiol. Immunol.</i> , Vol. 36, 1:55-66, 1992.	
*		Tokunaga et al., A Synthetic Single-Stranded DNA, Poly (dG, dC), Induces Interferon $\alpha/\beta$ and $\gamma$ , Augments Natural Killer Activity and Suppresses Tumor Growth. <i>Jpn. J. Cancer Res.</i> , 79:682-686, June 1988.	
*		Tsukada, J., et al., "Transcriptional Factors NF-IL6 and CREB Recognize a Common Essential Site in the Human prointerleukin 1 $\beta$ Gene", <i>Molecular and Cellular Biology</i> , 14:11:7285-7297, (1994)	
*		Uhlmann et al., Antisense Oligonucleotides: A New Therapeutic Principle. <i>Chemical Reviews</i> , 90:543-584, 1990.	
*		Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> , 372:L333-335, 1994.	
*		Wallace et al., Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods in Enzymology</i> , 152:432-442 (1987).	
*		Weiss R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics. <i>Science</i> , 139:108-109, 1991.	
*		Whalen R, DNA Vaccines for Emerging Infection Diseases: What If?, <i>Emerging Infectious Disease</i> , Vol. 2, 3:168-175, 1996.	
*		Wu GY. et al., Receptor-mediated gene delivery and expression in vivo. <i>J. Biol. Chem.</i> , 263:14621-14624, 1988.	
*		Wu-Pong S., Oligonucleotides: Opportunities for Drug Therapy and Research. <i>Pharmaceutical Technology</i> , 18:102-114, 1994.	

<b>FORM PTO-1449 (Modified)</b>		<b>ATTY. DOCKET NO.</b>	<b>SERIAL NO</b>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C01039.70077.US	Not Yet Assigned
		APPLICANT Krieg	
		FILING DATE July 14, 2003	GROUP Not Yet Assigned
*		Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol</i> 36(9):983-97, 1992.	
*		Yamamoto S et al., <i>In vitro</i> augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 79:866-73, Jul 1988.	
*		Yamamoto S., Mode of Action of Oligonucleotide Fraction Extracted from <i>Mycobacterium bovis</i> BCG, <i>Kekkaku</i> , Vol. 69, 9:29-32, 1994.	
*		Yamamoto S et al., Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity. <i>J. Immunol.</i> , Vol. 148, 12:4072-4076, June 15, 1992.	
*		Yamamoto T et al., Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length. <i>Antisense Res. and Devel.</i> , 4:119-123, 1994.	
*		Yamamoto et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity. <i>Microbiol. Immunol.</i> , Vol. 38, 10:831-836, 1994.	
*		Yamamoto T et al., Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes <i>in vitro</i> . <i>Jpn. J. Cancer Res.</i> , 85:775-779, 1994.	
*		Yi, Ae-Kyung et al., IFN- $\gamma$ Promotes IL-6 and IgM Secretion in Response to CpG Motifs in Bacterial DNA and Oligonucleotides, <i>The Journal of Immunology</i> , pp. 558-564 (1996).	
*		Yi, Ae-Kyung et al., Rapid Immune Activation by CpG Motifs in Bacterial DNA, <i>The Journal of Immunology</i> , pp. 5394-5402 (1996).	
*		Zelphati, O. et al., Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes, <i>Antisense Res. and Devel.</i> , 3:323, 1993.	
*		Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, 1 Dec 1994.	
*		Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993.	

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 08/738,652, filed October 30, 1996, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER 	DATE CONSIDERED 9-18-06
---	-------------------------

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/337,636, filed June 21, 1999, and relied upon for an earlier filing date under 35 USC 120.